Prostate Biopsy in the Case of PIRADS 5-Is Systematic Biopsy Mandatory?
Prostate Imaging Reporting and Data System
biopsy strategy
fusion biopsy
prostate cancer
systematic biopsy
targeted biopsy
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
28 Aug 2023
28 Aug 2023
Historique:
received:
13
05
2023
revised:
07
08
2023
accepted:
11
08
2023
medline:
9
9
2023
pubmed:
9
9
2023
entrez:
9
9
2023
Statut:
epublish
Résumé
Combining systematic biopsy (SB) with targeted biopsy (TB) in the case of a positive result from multiparametric magnetic resonance imaging (mpMRI) is a matter of debate. The Prostate Imaging Reporting and Data System (PIRADS) score of 5 indicates the highest probability of clinically significant prostate cancer (csPC) detection in TB. Potentially, omitting SB in the case of PIRADS 5 may have a marginal impact on the csPC detection rate. The aim of this study was to determine whether SB can be avoided in the case of PIRADS 5 and to identify potential factors allowing for performing TB only. This cohort study involved
Identifiants
pubmed: 37685679
pii: jcm12175612
doi: 10.3390/jcm12175612
pmc: PMC10488368
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Minerva Urol Nefrol. 2020 Oct;72(5):637-639
pubmed: 32495611
BJU Int. 2020 Feb;125(2):260-269
pubmed: 31306539
Eur Urol. 2019 Apr;75(4):582-590
pubmed: 30522912
Can Urol Assoc J. 2013 Nov-Dec;7(11-12):E722-7
pubmed: 24282465
Eur Urol Oncol. 2018 Oct;1(5):418-425
pubmed: 31158081
Int J Clin Oncol. 2020 Jan;25(1):175-186
pubmed: 31473884
Eur Urol. 2018 Jul;74(1):48-54
pubmed: 29566957
J Urol. 2010 Jan;183(1):126-31
pubmed: 19913257
Eur Urol Oncol. 2018 May;1(1):29-36
pubmed: 31100225
Iran J Radiol. 2015 Apr 22;12(2):e13257
pubmed: 26060552
Prostate Cancer Prostatic Dis. 2022 Apr;25(4):720-726
pubmed: 35027690
Urol Oncol. 2021 Apr;39(4):235.e1-235.e4
pubmed: 33451935
J Urol. 2021 Aug;206(2):289-297
pubmed: 33818141
Urology. 2019 Dec;134:168-172
pubmed: 31479660
Cochrane Database Syst Rev. 2019 Apr 25;4:CD012663
pubmed: 31022301
Front Oncol. 2022 Jan 24;11:824204
pubmed: 35141158
Eur Urol Oncol. 2020 Apr;3(2):216-223
pubmed: 31239236
Clin Genitourin Cancer. 2019 Oct;17(5):e860-e870
pubmed: 31281065
Urol Oncol. 2020 Nov;38(11):846.e9-846.e16
pubmed: 32576527
Lancet Oncol. 2019 Jan;20(1):100-109
pubmed: 30470502
N Engl J Med. 2020 Mar 5;382(10):917-928
pubmed: 32130814
World J Urol. 2021 Jul;39(7):2463-2467
pubmed: 32949254
Urol Oncol. 2022 Feb;40(2):59.e1-59.e5
pubmed: 34544650
Int Urol Nephrol. 2019 Sep;51(9):1545-1552
pubmed: 31190297
J Urol. 2021 Feb;205(2):444-451
pubmed: 33026934
Actas Urol Esp. 2017 Apr;41(3):155-161
pubmed: 27890493
Minerva Urol Nephrol. 2023 Feb;75(1):31-41
pubmed: 36626117
Eur Urol. 2019 May;75(5):712-720
pubmed: 30509763
World J Urol. 2016 Apr;34(4):525-32
pubmed: 26293117
Clin Genitourin Cancer. 2019 Jun;17(3):e664-e671
pubmed: 31003892
Cancers (Basel). 2022 Aug 17;14(16):
pubmed: 36010963
Br J Radiol. 2022 Mar 01;95(1131):20210886
pubmed: 34762506
Urology. 2002 Mar;59(3):405-8
pubmed: 11880081
Mol Clin Oncol. 2022 Jun 20;17(2):127
pubmed: 35832470
J Urol. 2017 Dec;198(6):1230-1240
pubmed: 28552708
Front Surg. 2022 Oct 06;9:1013389
pubmed: 36277287
Hum Pathol. 2010 Jun;41(6):781-93
pubmed: 20466122
Transl Androl Urol. 2020 Dec;9(6):2510-2518
pubmed: 33457225
Eur Urol. 2020 Aug;78(2):138-142
pubmed: 32268944
Health Technol Assess. 2003;7(14):1-88
pubmed: 12709289
Eur Urol. 2017 Apr;71(4):517-531
pubmed: 27568655
Eur Urol Oncol. 2020 Dec;3(6):739-747
pubmed: 32847747
Front Oncol. 2021 Feb 26;11:643051
pubmed: 33718240
Eur Urol. 2016 Jan;69(1):16-40
pubmed: 26427566
Diagnostics (Basel). 2021 Jul 26;11(8):
pubmed: 34441270